EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current and future advances in practice: IgG4-related disease

Zachary S Wallace, Guy Katz iD, Yasmin G Hernandez-Barco, Matthew C Baker iD

Rheumatology Advances in Practice · 14.03.2024 · 8 (2)

DOI: 10.1093/rap/rkae020 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Rheumatology Advances in Practice, online erschienen am 10.04.2024. Verfasst von Zachary S Wallace und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Massachusetts General Hospital, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

IgG4-related disease (IgG4-RD) is an increasingly recognized cause of fibroinflammatory lesions in patients of diverse racial and ethnic backgrounds and is associated with an increased risk of death. The aetiology of IgG4-RD is incompletely understood, but evidence to date suggests that B and T cells are important players in pathogenesis, both of which are key targets of ongoing drug development programmes. The diagnosis of IgG4-RD requires clinicopathological correlation because there is no highly specific or sensitive test. Glucocorticoids are highly effective, but their use is limited by toxicity, highlighting the need for studies investigating the efficacy of glucocorticoid-sparing agents. B cell-targeted therapies, particularly rituximab, have demonstrated benefit, but no randomized clinical trials have evaluated their efficacy. If untreated or under-treated, IgG4-RD can cause irreversible organ damage, hence close monitoring and consideration for long-term immunosuppression is warranted in certain cases.

Schlagwörter

Stichwörter der Autor:innen

IgG4-related diseaseepidemiologyglucocorticoidsoutcomesrituximabtreatment

Autor:innen und Institutionen

  • Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA.
  • Harvard Medical School, Harvard University, Boston, MA, USA.
  • Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA.
  • Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA.

ORCID-Profile: Guy Katz, Matthew C Baker

Förderung

  • NCI NIH HHS
  • Massachusetts General Hospital
  • National Institutes of Health

Zitieren

APA

Wallace, Z. S., Katz, G., Hernandez-Barco, Y. G., & Baker, M. C. (2024). Current and future advances in practice: IgG4-related disease. Rheumatology Advances in Practice, 8(2). https://doi.org/10.1093/rap/rkae020

Vancouver

Wallace ZS, Katz G, Hernandez-Barco YG, Baker MC. Current and future advances in practice: IgG4-related disease. Rheumatology Advances in Practice. 2024;8(2). doi:10.1093/rap/rkae020

BibTeX
@article{Wallace2024,
  author = {Wallace, Zachary S and Katz, Guy and Hernandez-Barco, Yasmin G and Baker, Matthew C},
  title = {Current and future advances in practice: IgG4-related disease},
  journal = {Rheumatology Advances in Practice},
  year = {2024},
  volume = {8},
  number = {2},
  doi = {10.1093/rap/rkae020}
}
Kostenlos starten →